# OnKure Therapeutics

OnKure Therapeutics is an Asset Manager based in Boulder, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Boulder, United States
- **Region:** North America
- **Address:** Boulder, CO, United States
- **Founded:** 2011
- **Assets under management:** Undisclosed
- **Website:** onkure.com
- **LinkedIn:** https://www.linkedin.com/company/onkure-tx

## Regulatory record

- **Reports private funds:** No

## About

OnKure Therapeutics launched in 2011 after Nicholas Saccomano, a former Array BioPharma and SomaLogic scientist, licensed foundational chemistry from the University of Colorado Boulder. The company's original focus was narrow: develop selective histone deacetylase inhibitors for cancers driven by specific epigenetic lesions, an area where broad-spectrum HDAC inhibitors had produced clinical responses but also dose-limiting toxicities. Early venture backing from Delian Capital and other life-science specialists funded a platform that has since expanded into phosphoinositide 3-kinase (PI3K) inhibitors. The firm's pipeline is built around two clinical-stage assets. OKI-179, an oral Class I HDAC inhibitor, has completed Phase 1 dose-escalation in advanced solid tumors and combines with binimetinib in NRAS-mutant melanoma. OKI-219, a mutant-selective PI3K-alpha H1047R inhibitor, targets one of the most common oncogenic driver mutations in breast cancer and entered the clinic in 2023. OnKure structures itself as a drug development engine rather than a discovery platform, in-licensing or acquiring assets that align with its translational biology team in Boulder, Colorado. The workforce is concentrated at the Boulder headquarters, where Saccomano manages a lean team of clinical and chemistry professionals. In May 2024 the firm merged with Reneo Pharmaceuticals in an all-stock transaction that effectively took OnKure public on Nasdaq under the ticker OKUR, providing Reneo's cash reserves for the Phase 1 work on OKI-219. The combined entity retained the OnKure name and pipeline. OnKure's structure sets it apart from most clinical-stage oncology companies because its pipeline was assembled through in-licensing and merger rather than internal target discovery. The Reneo reverse-merger was a capital-markets arbitrage that avoided a conventional biotech IPO roadshow, a model that several cash-constrained biotechs are now following. The firm's governance remains scientist-led, with Saccomano retaining control of R&D strategy while the merged company reports through public-market compliance channels.

## Sectors

- Digital Health
- Biotechnology

## People

- Nicholas Saccomano — Chief Scientific Officer
- Kirk L. Christoffersen — Chief Operating Officer

## Questions

### How does OnKure source its drug candidates?

OnKure in-licenses or acquires clinical-stage assets that match its translational biology team's expertise in epigenetic enzymes and kinase signaling. The original HDAC inhibitor chemistry came from the University of Colorado Boulder, and the company has maintained an external innovation sourcing model rather than building internal target-discovery capabilities.

### What differentiates OKI-179 from earlier HDAC inhibitors?

OKI-179 is an oral Class I-selective HDAC inhibitor designed to retain anti-tumor activity while reducing the hematologic and gastrointestinal toxicities seen with pan-HDAC inhibitors such as vorinostat. The compound has been studied in combination with the MEK inhibitor binimetinib in NRAS-mutant melanoma, a genetically defined population with limited targeted therapy options.

### Who controls R&D decisions at the merged company?

Nicholas Saccomano, the CSO and co-founder, retained direction of the R&D strategy after the Reneo merger. The combined board includes representatives from both legacy companies, but pipeline prioritization and clinical development decisions continue to be run out of the Boulder, Colorado site by the founding scientific team.

## Related profiles

- [SANUWAVE Health](https://altss.com/profile/sanuwave-health-inc)
- [Empro Group](https://altss.com/profile/empro-group-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/onkure-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology